Note 5 - Significant Risks and Uncertainties	3 Months Ended
Sep. 30, 2020
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 5. Significant Risks and Uncertainties ( a ) Major Customers. For the three months ended September 30, 2020 and 2019, approximately 92% and 91% of consolidated net sales, respectively, were derived from two customers. These two customers are in the Company's Contract Manufacturing Segment and represented approximately 69% and 25% and 66% and 29% in the three months ended September 30, 2020 and 2019, respectively. Accounts receivable from these two major customers represented approximately 89% and 92% of total net accounts receivable as of September 30 and June 30, 2020, respectively. The loss of any of these customers could have an adverse effect on the Company's operations. Major customers are those customers who account for more than 10% of net sales. ( b ) Other Business Risks. Approximately 69% of the Company's employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed on September 1, 2018 and will expire on August 31, 2021. The COVID- 19, or coronavirus, outbreak has the potential to cause a disruption in the Company's supply chain. Currently, some of our suppliers of certain materials used in the production of our supplements are located in China and other impacted countries or other states within the United States. Most of these materials may be obtained from more than one supplier. However, due to port closures and other restrictions resulting from the coronavirus outbreak throughout the world, these suppliers, located both inside and outside of the United States, may have limited supply of the materials, which has caused prices of some materials to increase. These and other disruptions would likely impact the Company's sales and operating results. If the Company is unable to obtain the necessary materials to produce a supplement within the Company's standard lead times, it may delay the production and shipment of those supplements, thereby shifting the timing of recognizing the resulting sale to the Company's customers. In addition, the significant outbreak of this contagious disease in the human population has resulted in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for the Company's products and impact the Company's operating results. The Company does not currently anticipate any negative impact to its margins resulting from the coronavirus outbreak, however; if the Company is unable to obtain the necessary materials to produce a supplement within its standard lead times or the necessary safety and cleaning supplies it may delay the production and shipment of those supplements to its customers, thereby shifting the timing of recognizing the resulting sale to its customers.

Note

Significant Risks and Uncertainties

(

) Major Customers.

For the

three

months ended

September 30, 2020

and

2019,

approximately

92%

and

91%

of consolidated net sales, respectively, were derived from

two

customers. These

two

customers are in the Company's Contract Manufacturing Segment and represented approximately

69%

and

25%

and

66%

and

29%

in the

three

months ended

September 30, 2020

and

2019,

respectively. Accounts receivable from these

two

major customers represented approximately

89%

and

92%

of total net accounts receivable as of

September 30

and

June 30, 2020,

respectively. The loss of any of these customers could have an adverse effect on the Company's operations. Major customers are those customers who account for more than

10%

of net sales.

(

) Other Business Risks.

Approximately

69%

of the Company's employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed on

September 1, 2018

and will expire on

August 31, 2021.

The COVID-

19,

or coronavirus, outbreak has the potential to cause a disruption in the Company's supply chain. Currently, some of our suppliers of certain materials used in the production of our supplements are located in China and other impacted countries or other states within the United States. Most of these materials

may

be obtained from more than

one

supplier. However, due to port closures and other restrictions resulting from the coronavirus outbreak throughout the world, these suppliers, located both inside and outside of the United States,

may

have limited supply of the materials, which has caused prices of some materials to increase. These and other disruptions would likely impact the Company's sales and operating results. If the Company is unable to obtain the necessary materials to produce a supplement within the Company's standard lead times, it

may

delay the production and shipment of those supplements, thereby shifting the timing of recognizing the resulting sale to the Company's customers. In addition, the significant outbreak of this contagious disease in the human population has resulted in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for the Company's products and impact the Company's operating results.

The Company does

not

currently anticipate any negative impact to its margins resulting from the coronavirus outbreak, however; if the Company is unable to obtain the necessary materials to produce a supplement within its standard lead times or the necessary safety and cleaning supplies it

may

delay the production and shipment of those supplements to its customers, thereby shifting the timing of recognizing the resulting sale to its customers.